**Supplementary Table 3A. Proliferation results of combined treatment of luteolin and PARP inhibitor (Olaparib).**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Single treatment** | | **Combined treatment** | | | CI | **Combined**  **Effect** |
| Olaparib dose /μM | Cell confluence | Luteolin dose/μM | Olaparib dose /μM | Cell confluence |
| **U251** |  |  |  |  |  |  |
| 0 | 100 | 1.5 | 0 | 87.62 |  |  |
| 0.5 | 92.97 | 1.5 | 0.5 | 52.04 | 0.638 | **synergistic** |
| 0.75 | 76.97 | 1.5 | 0.75 | 48.41 | 0.718 | **synergistic** |
| **U343** |  |  |  |  |  |  |
| 0 | 100 | 5 | 0 | 94.58 |  |  |
| 10 | 76.23 | 5 | 10 | 65.74 | 0.912 | **synergistic** |
| 15 | 63.66 | 5 | 15 | 41.73 | 0.693 | **synergistic** |

**Supplementary Table 3B. Colony formation results of combined treatment of luteolin and PARP inhibitor (Olaparib).**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Single treatment** | | **Combined treatment** | | | CI | **Combined**  **Effect** |
| Olaparib dose /μM | Relative OD560nm | Luteolin dose/μM | Olaparib dose /μM | Relative OD560nm |
| **U251** |  |  |  |  |  |  |
| 0 | 1 | 1.5 | 0 | 0.837 |  |  |
| 0.5 | 0.933 | 1.5 | 0.5 | 0.471 | 0.604 | **synergistic** |
| 0.75 | 0.763 | 1.5 | 0.75 | 0.455 | 0.712 | **synergistic** |
| **U343** |  |  |  |  |  |  |
| 0 | 1 | 5 | 0 | 0.941 |  |  |
| 10 | 0.710 | 5 | 10 | 0.575 | 0.861 | **synergistic** |
| 15 | 0.595 | 5 | 15 | 0.394 | 0.704 | **synergistic** |